Pharma: Clinic Roundup

• Upsher-Smith Laboratories Inc., of San Diego, said Phase I data showing that USL261 (intranasal midazolam) demonstrated that maximum midazolam plasma concentrations were rapidly achieved after dosing, and both midazolam and its metabolite were rapidly eliminated.